We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-9.95%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$521M
AUM Growth
-$149M
(-22%)
Cap. Flow
-$67.8M
Cap. Flow
% of AUM
-13.02%
Top 10 Holdings %
Top 10 Hldgs %
35.83%
Holding
77
New
12
Increased
14
Reduced
37
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$13M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$11.3M |
| 3 |
PPD
PPD, Inc. Common Stock
PPD
|
+$11.2M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$10.2M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$14.5M |
| 2 |
Teladoc Health
TDOC
|
+$14.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$11.8M |
| 4 |
STML
Stemline Therapeutics, Inc.
STML
|
+$10.9M |
| 5 |
Tandem Diabetes Care
TNDM
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.94% |
| 2 | Industrials | 4.93% |
| 3 | Technology | 1.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Regeneron Pharmaceuticals
REGN
$78.1B
| $3.79M | 0.73% |
+7,770
| New | +$3.21M |
|
52
Medtronic
MDT
$110B
| $3.77M | 0.72% |
41,751
-13,400
| -24% | -$1.43M |
|
53
NextCure
NXTC
$22M
| $3.67M | 0.71% |
8,262
-2,155
| -21% | -$1.15M |
|
54
Arcus Biosciences
RCUS
$3.57B
| $3.63M | 0.7% |
+261,213
| New | +$3.25M |
|
55
Amgen
AMGN
$207B
| $2.92M | 0.56% |
14,403
-2,000
| -12% | -$437K |
|
56
Illumina
ILMN
$29.8B
| $2.44M | 0.47% |
9,180
-843
| -8% | -$236K |
|
|
VCRA
57
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $1.44M | 0.28% |
67,896
-517,632
| -88% | -$11.8M |
|
58
Incyte
INCY
$24.1B
| $1.25M | 0.24% |
17,000
+2,000
| +13% | +$151K |
|
59
Pfizer
PFE
$144B
| $1.14M | 0.22% |
+36,890
| New | +$1.26M |
|
60
MeiraGTx Holdings
MGTX
$1.13B
| $867K | 0.17% |
64,534
-28,772
| -31% | -$486K |
|
61
Moderna
MRNA
$22.7B
| $659K | 0.13% |
+22,000
| New | +$506K |
|
62
Guardant Health
GH
$21.4B
| $644K | 0.12% |
+9,250
| New | +$710K |
|
63
Q32 Bio
QTTB
$453M
| $595K | 0.11% |
2,127
-300
| -12% | -$91.9K |
|
64
CRISPR Therapeutics
CRSP
$5.06B
| $456K | 0.09% |
+10,750
| New | +$555K |
|
65
Dr. Reddy's Laboratories
RDY
$10B
| $297K | 0.06% |
36,770
-41,000
| -53% | -$342K |
|
66
Agios Pharmaceuticals
AGIO
$1.84B
| – | – |
-34,100
| Closed | -$1.63M |
|
|
BPMC
67
DELISTED
Blueprint Medicines
BPMC
| – | – |
-45,000
| Closed | -$3.6M |
|
68
Cogent Biosciences
COGT
$7.27B
| – | – |
-36,686
| Closed | -$106K |
|
|
SAGE
69
DELISTED
Sage Therapeutics
SAGE
| – | – |
-7,650
| Closed | -$552K |
|
70
Thermo Fisher Scientific
TMO
$208B
| – | – |
-11,750
| Closed | -$3.82M |
|
71
Vericel Corp
VCEL
$2.35B
| – | – |
-138,000
| Closed | -$2.4M |
|
72
Zimmer Biomet
ZBH
$18.4B
| – | – |
-50,726
| Closed | -$7.37M |
|
|
EVLO
73
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| – | – |
-31,629
| Closed | -$2.57M |
|
|
PHAS
74
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| – | – |
-178,000
| Closed | -$1.09M |
|
|
ALXN
75
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-25,399
| Closed | -$2.75M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q1 2020 Portfolio in Review
As of Q1 2020, Sectoral Asset Management held 77 positions worth $521M, down 22% from $670M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sectoral Asset Management withdrew a net $67.8M in Q1 2020, closing 12 positions and reducing 37 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $14.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Industrials and Technology.
Against the trend, Sectoral Asset Management opened a new position in Exelixis worth $12.2M.
- Sectoral Asset Management's largest Q1 2020 buy was Exelixis: 708,090 shares worth $12.2M.
- Sectoral Asset Management added most to Seagen Inc. Common Stock in Q1 2020, an estimated $10.2M increase.
- Sectoral Asset Management's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $14.3M.
- Sectoral Asset Management fully exited Portola Pharmaceuticals, Inc. in Q1 2020, selling an estimated $14.5M.
- Sectoral Asset Management's ten largest holdings make up 36% of its $521M portfolio in Q1 2020.
- Sectoral Asset Management opened 12 new positions and closed 12 in Q1 2020.
- Sectoral Asset Management's portfolio value fell 22% quarter-over-quarter to $521M.
Based on Sectoral Asset Management's 13F filing for Q1 2020, filed 13 May 2020.